MedPath

Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers

Phase 1
Completed
Conditions
Adult Healthy Volunteers
Registration Number
NCT01885624
Lead Sponsor
Theramab LLC
Brief Summary

The purpose of this study is to assess safety and tolerability of ascending dosed of TAB08 after single i.v. infusion to the adult healthy volunteers. Additionally were assessed infusion speed tolerability, pharmacokinetics and pharmacodynamics of TAB08 after single i.v. infusion and to explore TAB mechanism-of-action biomarkers.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
31
Inclusion Criteria
  • Adult man aged from 18 to 40 years, who agreed to use adequate contraception.
  • Body mass is at least 60 kg and BMI is within 20-27
  • Volunteer is in good physical and mental health, as per his medical history and assessment results
  • Volunteer's laboratory values are normal (or not clinically significant as per Investigator discretion) at screening, including baseline cytokines levels as per RESTORE test results
  • Volunteer has signed the informed concent.
Exclusion Criteria
  • Any chronic or relapsing illness in the medical history
  • Any abnormal assessment or laboratory result at screening, which is clinically significant as per Investigator discretion
  • Active tuberculosis at the time of screening
  • Any acute illness at the time of study enrollment
  • Any blood donation within 4 weeks before Study Day 1
  • Positive result for HBsAG, Hepatitis C, HIV
  • Continuous use af any medications
  • Use of any medications within 72 hours before study drug infusion
  • Use of an investigational treatment within 4 weeks before screening, or within a period of 5 half-lives of the investigational treatment, whichever is longer
  • High inflammatory cytokines levels as per RESTORE test results after ex vivo PBMC testing

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Incidence of dose-limiting toxicity in every dose cohortFrom study drug infusion (Day 1) untill the end of study (Day 71/141)
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Clinical Emergency Hospital of Yaroslavl

🇷🇺

Yaroslavl, Russian Federation

Clinical Emergency Hospital of Yaroslavl
🇷🇺Yaroslavl, Russian Federation

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.